Other
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
ASCO Presentation Offers No New Catalysts as Dilutive Capital Raise Extends Runway Amid Steep Equity Erosion
Executive Summary
- Medicenna Therapeutics announced the presentation of the NEO-CYT Phase 1b trial at the 2026 ASCO Annual Meeting.
- The trial evaluates MDNA11 combined with checkpoint inhibitors (nivolumab ± ipilimumab) as neoadjuvant therapy for high-risk, surgically resectable Stage III melanoma.
- The study aims to surpass the current standard of care (ipilimumab + nivolumab) by leveraging MDNA11's beta-enhanced IL-2 Superkine mechanism to improve Major Pathologic Response (MPR) rates.
- Clinical data updates for both NEO-CYT and the ongoing Phase 1/2 ABILITY-1 study are expected in the second half of 2026.
- This follows the May 12, 2026 announcement of the first patient dosing in NEO-CYT and the May 21/28, 2026 closing of a $4.44M public offering plus an $8.0M structured financing agreement.
Material Impact
- The ASCO presentation is a scheduled, investigator-sponsored academic update. It does not contain new clinical data, efficacy endpoints, or safety signals that would alter the investment thesis.
- The news is a direct follow-up to the May 12 first-patient-dosing announcement and aligns with the company's stated H2 2026 data timeline.
- The market has already priced in the capital raise (May 2026) and the clinical progression. Without specific data highlights or regulatory milestones, the presentation is incremental and expected.
- The stock's recent decline from $1.64 to $0.42 reflects broader biotech sentiment, dilution from the $0.50/unit offering, and the absence of near-term catalysts. This release does not reverse that trajectory.
MDNA · Price
Company Overview
- Medicenna Therapeutics is a clinical-stage biotechnology company focused on engineered cytokine therapies for oncology and inflammatory diseases.
- Flagship asset: MDNA11, a long-acting, beta-enhanced IL-2 Superkine designed to preferentially activate CD8+ T cells and NK cells while sparing regulatory T cells (Tregs).
- Pipeline:
- MDNA11: Phase 1/2 ABILITY-1 study in advanced solid tumors; Phase 1b NEO-CYT neoadjuvant melanoma trial.
- MDNA113: First-in-class tumor-anchored, conditionally activated anti-PD-1 x IL-2 bifunctional superkine. Preclinical data shows superior tolerability in non-human primates. IND filing targeted for H2 2026.
- Bizaxofusp (MDNA55): IL-4 Empowered Superkine for recurrent glioblastoma. Phase 2b data showed median OS of 13.6 months vs 7 months standard care. Seeking partnership.
- Development strategy relies on combination immunotherapy regimens and expanding into earlier-line settings (neoadjuvant) and broader solid tumor indications.
More from MEDICENNA THERAPEUTICS CORP. J
Jun 26, 2026 · 08:45